The Global Market for Oligonucleotide Therapeutics is estimated to be worth $2.5 Billion by 2027. The global oligonucleotide therapeutics market is marked with presence of quite a few prominent players, thereby making it a fairly competitive market for both the existing players and new entrants. Oligonucleotide Therapy Global Market Report 2021: COVID-19 Growth and Change to 2030 provides the strategists, marketers and senior management with the critical information they need to assess the global oligonucleotide therapy market. We use cookies for a better user experience. This product is a market research report. See how our work could benefit your research, analyses, and decisions. How will the composition of the market change during that time, and why? HVAC (Heating, Ventilation, & Air Conditioning), Global Oligonucleotide Therapeutics Market Research Report 2022 (Status and Outlook), Antisense Oligonucleotide Therapeutics - Pipeline Insight, 2022, Oligonucleotide Therapeutic Drugs Global Market Insights 2022, Analysis and Forecast to 2027, by Manufacturers, Regions, Technology, Product Type, Oligonucleotide Synthesis Market Research Report by Product (Equipment, Reagents, and Synthesized Oligos), Application, End User, Region (Americas, Asia-Pacific, and Europe, Middle East & Africa) - Global Forecast to 2027 - Cumulative Impact of COVID-19, Impact of Covid-19 and a Looming Global Recession, Table 1: World Current & Future Analysis for Oligonucleotide Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR, Table 2: World Historic Review for Oligonucleotide Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR, Table 3: World 15-Year Perspective for Oligonucleotide Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2020 & 2027, Table 4: World Current & Future Analysis for Neurological Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR, Table 5: World Historic Review for Neurological Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR, Table 6: World 15-Year Perspective for Neurological Disorders by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027, Table 7: World Current & Future Analysis for Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR, Table 8: World Historic Review for Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR, Table 9: World 15-Year Perspective for Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027, Table 10: World Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR, Table 11: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR, Table 12: World 15-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027, Table 13: World Current & Future Analysis for Antisense/RNAI Oligonucleotides by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR, Table 14: World Historic Review for Antisense/RNAI Oligonucleotides by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR, Table 15: World 15-Year Perspective for Antisense/RNAI Oligonucleotides by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027, Table 16: World Current & Future Analysis for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR, Table 17: World Historic Review for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR, Table 18: World 15-Year Perspective for Other Technologies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027, Table 19: USA Current & Future Analysis for Oligonucleotide Therapeutics by Application - Neurological Disorders, Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR, Table 20: USA Historic Review for Oligonucleotide Therapeutics by Application - Neurological Disorders, Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR, Table 21: USA 15-Year Perspective for Oligonucleotide Therapeutics by Application - Percentage Breakdown of Value Sales for Neurological Disorders, Cancer and Other Applications for the Years 2012, 2020 & 2027, Table 22: USA Current & Future Analysis for Oligonucleotide Therapeutics by Technology - Antisense/RNAI Oligonucleotides and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR, Table 23: USA Historic Review for Oligonucleotide Therapeutics by Technology - Antisense/RNAI Oligonucleotides and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR, Table 24: USA 15-Year Perspective for Oligonucleotide Therapeutics by Technology - Percentage Breakdown of Value Sales for Antisense/RNAI Oligonucleotides and Other Technologies for the Years 2012, 2020 & 2027, Table 25: Canada Current & Future Analysis for Oligonucleotide Therapeutics by Application - Neurological Disorders, Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR, Table 26: Canada Historic Review for Oligonucleotide Therapeutics by Application - Neurological Disorders, Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR, Table 27: Canada 15-Year Perspective for Oligonucleotide Therapeutics by Application - Percentage Breakdown of Value Sales for Neurological Disorders, Cancer and Other Applications for the Years 2012, 2020 & 2027, Table 28: Canada Current & Future Analysis for Oligonucleotide Therapeutics by Technology - Antisense/RNAI Oligonucleotides and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR, Table 29: Canada Historic Review for Oligonucleotide Therapeutics by Technology - Antisense/RNAI Oligonucleotides and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR, Table 30: Canada 15-Year Perspective for Oligonucleotide Therapeutics by Technology - Percentage Breakdown of Value Sales for Antisense/RNAI Oligonucleotides and Other Technologies for the Years 2012, 2020 & 2027, Table 31: Japan Current & Future Analysis for Oligonucleotide Therapeutics by Application - Neurological Disorders, Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR, Table 32: Japan Historic Review for Oligonucleotide Therapeutics by Application - Neurological Disorders, Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR, Table 33: Japan 15-Year Perspective for Oligonucleotide Therapeutics by Application - Percentage Breakdown of Value Sales for Neurological Disorders, Cancer and Other Applications for the Years 2012, 2020 & 2027, Table 34: Japan Current & Future Analysis for Oligonucleotide Therapeutics by Technology - Antisense/RNAI Oligonucleotides and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR, Table 35: Japan Historic Review for Oligonucleotide Therapeutics by Technology - Antisense/RNAI Oligonucleotides and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR, Table 36: Japan 15-Year Perspective for Oligonucleotide Therapeutics by Technology - Percentage Breakdown of Value Sales for Antisense/RNAI Oligonucleotides and Other Technologies for the Years 2012, 2020 & 2027, Table 37: China Current & Future Analysis for Oligonucleotide Therapeutics by Application - Neurological Disorders, Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR, Table 38: China Historic Review for Oligonucleotide Therapeutics by Application - Neurological Disorders, Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR, Table 39: China 15-Year Perspective for Oligonucleotide Therapeutics by Application - Percentage Breakdown of Value Sales for Neurological Disorders, Cancer and Other Applications for the Years 2012, 2020 & 2027, Table 40: China Current & Future Analysis for Oligonucleotide Therapeutics by Technology - Antisense/RNAI Oligonucleotides and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR, Table 41: China Historic Review for Oligonucleotide Therapeutics by Technology - Antisense/RNAI Oligonucleotides and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR, Table 42: China 15-Year Perspective for Oligonucleotide Therapeutics by Technology - Percentage Breakdown of Value Sales for Antisense/RNAI Oligonucleotides and Other Technologies for the Years 2012, 2020 & 2027, Table 43: Europe Current & Future Analysis for Oligonucleotide Therapeutics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR, Table 44: Europe Historic Review for Oligonucleotide Therapeutics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR, Table 45: Europe 15-Year Perspective for Oligonucleotide Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2020 & 2027, Table 46: Europe Current & Future Analysis for Oligonucleotide Therapeutics by Application - Neurological Disorders, Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR, Table 47: Europe Historic Review for Oligonucleotide Therapeutics by Application - Neurological Disorders, Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR, Table 48: Europe 15-Year Perspective for Oligonucleotide Therapeutics by Application - Percentage Breakdown of Value Sales for Neurological Disorders, Cancer and Other Applications for the Years 2012, 2020 & 2027, Table 49: Europe Current & Future Analysis for Oligonucleotide Therapeutics by Technology - Antisense/RNAI Oligonucleotides and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR, Table 50: Europe Historic Review for Oligonucleotide Therapeutics by Technology - Antisense/RNAI Oligonucleotides and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR, Table 51: Europe 15-Year Perspective for Oligonucleotide Therapeutics by Technology - Percentage Breakdown of Value Sales for Antisense/RNAI Oligonucleotides and Other Technologies for the Years 2012, 2020 & 2027, Table 52: France Current & Future Analysis for Oligonucleotide Therapeutics by Application - Neurological Disorders, Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR, Table 53: France Historic Review for Oligonucleotide Therapeutics by Application - Neurological Disorders, Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR, Table 54: France 15-Year Perspective for Oligonucleotide Therapeutics by Application - Percentage Breakdown of Value Sales for Neurological Disorders, Cancer and Other Applications for the Years 2012, 2020 & 2027, Table 55: France Current & Future Analysis for Oligonucleotide Therapeutics by Technology - Antisense/RNAI Oligonucleotides and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR, Table 56: France Historic Review for Oligonucleotide Therapeutics by Technology - Antisense/RNAI Oligonucleotides and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR, Table 57: France 15-Year Perspective for Oligonucleotide Therapeutics by Technology - Percentage Breakdown of Value Sales for Antisense/RNAI Oligonucleotides and Other Technologies for the Years 2012, 2020 & 2027, Table 58: Germany Current & Future Analysis for Oligonucleotide Therapeutics by Application - Neurological Disorders, Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR, Table 59: Germany Historic Review for Oligonucleotide Therapeutics by Application - Neurological Disorders, Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR, Table 60: Germany 15-Year Perspective for Oligonucleotide Therapeutics by Application - Percentage Breakdown of Value Sales for Neurological Disorders, Cancer and Other Applications for the Years 2012, 2020 & 2027, Table 61: Germany Current & Future Analysis for Oligonucleotide Therapeutics by Technology - Antisense/RNAI Oligonucleotides and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR, Table 62: Germany Historic Review for Oligonucleotide Therapeutics by Technology - Antisense/RNAI Oligonucleotides and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR, Table 63: Germany 15-Year Perspective for Oligonucleotide Therapeutics by Technology - Percentage Breakdown of Value Sales for Antisense/RNAI Oligonucleotides and Other Technologies for the Years 2012, 2020 & 2027, Table 64: Italy Current & Future Analysis for Oligonucleotide Therapeutics by Application - Neurological Disorders, Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR, Table 65: Italy Historic Review for Oligonucleotide Therapeutics by Application - Neurological Disorders, Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR, Table 66: Italy 15-Year Perspective for Oligonucleotide Therapeutics by Application - Percentage Breakdown of Value Sales for Neurological Disorders, Cancer and Other Applications for the Years 2012, 2020 & 2027, Table 67: Italy Current & Future Analysis for Oligonucleotide Therapeutics by Technology - Antisense/RNAI Oligonucleotides and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR, Table 68: Italy Historic Review for Oligonucleotide Therapeutics by Technology - Antisense/RNAI Oligonucleotides and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR, Table 69: Italy 15-Year Perspective for Oligonucleotide Therapeutics by Technology - Percentage Breakdown of Value Sales for Antisense/RNAI Oligonucleotides and Other Technologies for the Years 2012, 2020 & 2027, Table 70: UK Current & Future Analysis for Oligonucleotide Therapeutics by Application - Neurological Disorders, Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR, Table 71: UK Historic Review for Oligonucleotide Therapeutics by Application - Neurological Disorders, Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR, Table 72: UK 15-Year Perspective for Oligonucleotide Therapeutics by Application - Percentage Breakdown of Value Sales for Neurological Disorders, Cancer and Other Applications for the Years 2012, 2020 & 2027, Table 73: UK Current & Future Analysis for Oligonucleotide Therapeutics by Technology - Antisense/RNAI Oligonucleotides and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR, Table 74: UK Historic Review for Oligonucleotide Therapeutics by Technology - Antisense/RNAI Oligonucleotides and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR, Table 75: UK 15-Year Perspective for Oligonucleotide Therapeutics by Technology - Percentage Breakdown of Value Sales for Antisense/RNAI Oligonucleotides and Other Technologies for the Years 2012, 2020 & 2027, Table 76: Rest of Europe Current & Future Analysis for Oligonucleotide Therapeutics by Application - Neurological Disorders, Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR, Table 77: Rest of Europe Historic Review for Oligonucleotide Therapeutics by Application - Neurological Disorders, Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR, Table 78: Rest of Europe 15-Year Perspective for Oligonucleotide Therapeutics by Application - Percentage Breakdown of Value Sales for Neurological Disorders, Cancer and Other Applications for the Years 2012, 2020 & 2027, Table 79: Rest of Europe Current & Future Analysis for Oligonucleotide Therapeutics by Technology - Antisense/RNAI Oligonucleotides and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR, Table 80: Rest of Europe Historic Review for Oligonucleotide Therapeutics by Technology - Antisense/RNAI Oligonucleotides and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR, Table 81: Rest of Europe 15-Year Perspective for Oligonucleotide Therapeutics by Technology - Percentage Breakdown of Value Sales for Antisense/RNAI Oligonucleotides and Other Technologies for the Years 2012, 2020 & 2027, Table 82: Asia-Pacific Current & Future Analysis for Oligonucleotide Therapeutics by Application - Neurological Disorders, Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR, Table 83: Asia-Pacific Historic Review for Oligonucleotide Therapeutics by Application - Neurological Disorders, Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR, Table 84: Asia-Pacific 15-Year Perspective for Oligonucleotide Therapeutics by Application - Percentage Breakdown of Value Sales for Neurological Disorders, Cancer and Other Applications for the Years 2012, 2020 & 2027, Table 85: Asia-Pacific Current & Future Analysis for Oligonucleotide Therapeutics by Technology - Antisense/RNAI Oligonucleotides and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR, Table 86: Asia-Pacific Historic Review for Oligonucleotide Therapeutics by Technology - Antisense/RNAI Oligonucleotides and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR, Table 87: Asia-Pacific 15-Year Perspective for Oligonucleotide Therapeutics by Technology - Percentage Breakdown of Value Sales for Antisense/RNAI Oligonucleotides and Other Technologies for the Years 2012, 2020 & 2027, Table 88: Rest of World Current & Future Analysis for Oligonucleotide Therapeutics by Application - Neurological Disorders, Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR, Table 89: Rest of World Historic Review for Oligonucleotide Therapeutics by Application - Neurological Disorders, Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR, Table 90: Rest of World 15-Year Perspective for Oligonucleotide Therapeutics by Application - Percentage Breakdown of Value Sales for Neurological Disorders, Cancer and Other Applications for the Years 2012, 2020 & 2027, Table 91: Rest of World Current & Future Analysis for Oligonucleotide Therapeutics by Technology - Antisense/RNAI Oligonucleotides and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR, Table 92: Rest of World Historic Review for Oligonucleotide Therapeutics by Technology - Antisense/RNAI Oligonucleotides and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR, Table 93: Rest of World 15-Year Perspective for Oligonucleotide Therapeutics by Technology - Percentage Breakdown of Value Sales for Antisense/RNAI Oligonucleotides and Other Technologies for the Years 2012, 2020 & 2027. According to the American Cancer Society, there were 1.7 million new cases and 0.6 million cancer deaths in 2019 in the USA. In addition, commercialization of new molecules and consolidation of market is likely to play important role for the development of the regional market in the years to come. Profesoras, profesores, estudiantes: Each license type allows a set number of users to access the report. This product is a market research report. There exists nearly 135 oligonucleotide therapeutics that are in various phases of development of drugs. Sara Peerun Commercial Director Visiongain Inc. Tel:+ 44 207 549 9987 USA Tel:00 1 718 682 4567 EU Tel:00 353 1 695 0006 Email:sara.peerun@visiongain.com Web:https://www.visiongain.com/ Follow Us:LinkedIn|Twitter, A SWOT and Porters Five Forces analysis of the global. The new and innovative oligonucleotides allow precision medicine approaches and can be designed to selectively target any gene with minimal side effects. Free Customization as per your requirement, You will get Custom Report at Syndicated Report price. July 05, 2021 13:26 ET The Global Market for Oligonucleotide Therapeutics was estimated to be valued at $1.4 Billion in 2020. vico therapeutics organisations This factor offers a plethora of opportunities to the players in the global oligonucleotide therapeutics market for the development of new molecular entities. What are the main trends that will affect the world antisense oligonucleotide therapeutics market between 2021 and 2031? This is a single user license, allowing one user access to the product. Global Oligonucleotide Therapy Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion, 6.2. Our customized and syndicated market research reports means that you can have a bespoke piece of market intelligence customized to your very own business needs. Global market is expected to grow at a CAGR of 13.5% during the forecast period 2021-2031. Therefore, the rise in cancer incidence rate globally is anticipated to boost the demand for the oligonucleotide therapy market over the forthcoming years.Key Topics Covered: 1. | Source: Sitio desarrollado en el rea de Tecnologas Para el AprendizajeCrditos de sitio || Aviso de confidencialidad || Poltica de privacidad y manejo de datos. North America is likely to emerge as leading regional force in the global oligonucleotide therapeutics market throughout the tenure of assessment. In Dec 2016, US-based Biogen LLC obtained nod from US Food and Drug Administration (FDA) for nusinersens new drug application.

17 - 19 de Mayo, Pabelln Innovacin, Calidad y Ambientes de Aprendizaje, UdeG presente en Jalisco Talent Land 2022, UdeG ser sede de la Cumbre Internacional del Hbitat de Amrica Latina y El Caribe, Abren licenciatura en Construccin de Paz y Seguridad en CUTlajomulco para el calendario 2022-B, Destaca publicacin internacional diseo arquitectnico del MCA, UdeG tendr oferta cultural durante vacaciones de verano 2022, Ransomware attacks against higher ed increase, Fate of student loan payment pause, debt relief remains unclear, Community college program aims to train media influencers, Retired NYU administrator's novel "inspired by" his work, New presidents or provosts: Bluefield Carey Greenfield Ivy Tech Lipscomb Newark North Idaho SLCC Santa Barbara Wentworth.